13 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
transparency to product pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare … or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures
F-3
OBSVF
ObsEva SA
9 Dec 22
Shelf registration (foreign)
7:06am
, the transparency and availability of trading prices, the liquidity of the warrants and the extent of issuer regulation. Prospective purchasers of our
6-K
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review … price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures
6-K
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing … and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls
6-K
EX-99.1
3rr4mmp8
7 Aug 19
Current report (foreign)
7:21am
20-F
trfivq8epgg1dlb58k1y
21 Apr 17
Annual report (foreign)
12:00am
F-1
8zfs0 chwt95r
30 Dec 16
Registration statement (foreign)
12:00am
DRS
jvexv 1mlph5kv
14 Oct 16
Draft registration statement
12:00am
- Prev
- 1
- Next